NCE-1 Intelligence & Market Opportunity

Inluriyo

Imlunestrant

Anticancer

Oral Tablet

Inluriyo is an oral selective estrogen receptor degrader (SERD) indicated for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer. It degrades estrogen receptors to block tumor growth, offering a convenient daily oral option.

Approval Date

25-Sep-25

NCE-1 Date

25-Sep-29

NCE Date

25-Sep-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

157.86%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

137

2027

257

2028

435

2029

619

2030

825

2031

1,005

2032

1,166

Molecule profile

Details & specifications

Molecule

Imlunestrant

Innovator

ELI LILLY AND COMPANY

Dosage Form

Oral Tablet

Strength

200 mg

Therapeutic Category

Anticancer

Usage

To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets